Inflammatory actions of adiponectin, leptin, and resistin

Adipose Tissue and Inflammation

Volumn , Issue , 2009, Pages 167-187

  Stringer, Danielle M ^a   DeClercq, Vanessa C ^a   Hunt, Ryan W T ^a   Baranowski, Maria S ^a   Taylor, Carla G ^a   Zahradka, Peter ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77952521490     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (168)

1. DeClercq V, Taylor C, and Zahradka P. Adipose tissue: the link between obesity and cardiovascular disease. Cardiovasc Hematol Disord Drug Targets 2008; 8: 228-237.
2. Ahima RS. Revisiting leptin’s role in obesity and weight loss. J Clin Invest 2008; 118:2380-2383.
3. McTernan PG et al. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 2003; 88:6098-6106.
4. Florez H et al. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract 2006; 71: 92-100.
5. Bruun JM et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003; 285:E527-E533.
6. Beltowski J, Jamroz-Wisniewska A, and Widomska S. Adiponectin and its role in cardiovascular diseases. Cardiovasc Hematol Disord Drug Targets 2008; 8: 7-46.
7. Ouchi N et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107: 671-674.
8. Takemura Y, Walsh K, and Ouchi N. Adiponectin and cardiovascular inflammatory responses. Curr Atheroscler Rep 2007; 9: 238-243.
9. Avram MM, Avram AS, and James WD. Subcutaneous fat in normal and diseased states 3. Adipogenesis: from stem cell to fat cell. J Am Acad Dermatol 2007; 56: 472-492.
10. DeFronzo RA. Dysfunctional fat cells, lipotoxicity and type 2 diabetes. Int J Clin Pract 2004; 143: 9-21.
11. Ahima RS. Adipose tissue as an endocrine organ. Obesity 2006; 14: 242S-249S.
12. Hu E, Liang P, and Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697-10703.
13. Fain JN et al. Resistin release by human adipose tissue explants in primary culture. Biochem Biophys Res Commun 2003; 300: 674-678.
14. Bastard JP et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006; 17: 4-12.
15. Cancello R et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005; 54: 2277-2286.
16. Noto A et al. Dietary conjugated linoleic acid decreases adipocyte size and favorably modifies adipokine status and insulin sensitivity in obese, insulin-resistant rats. Metabolism 2007; 56: 1601-1611.
17. Kissebah AH et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci USA 2000; 97: 14478-14483.
18. Scherer PE et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-26749.
19. Maeda K et al. cDNA cloning and expression of a novel adipose specific collagenlike factor, apM1 (AdiPose Most abundant gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-289.
20. Nakano Y et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 1996; 120: 803-812.
21. Kobayashi H et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004; 94: e27-e31.
22. Pajvani UB et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 279: 12152-12162.
23. Tsao TS, Lodish HF, and Fruebis J. ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol 2002; 440: 213-221.
24. Tsao TS et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity: different oligomers activate different signal transduction pathways. J Biol Chem 2003; 278: 50810-50817.
25. Xu A et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 2005; 280: 18073-18080.
26. Ouchi N et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057-1063.
27. Wang Y et al. Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. J Biol Chem 2006; 281: 16391-16400.
28. Bobbert T et al. Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 2005; 54: 2712-2719.
29. Polak J et al. Total adiponectin and adiponectin multimeric complexes in relation to weight loss-induced improvements in insulin sensitivity in obese women: NUGENOB study. Eur J Endocrinol 2008; 158: 533-541.
30. Yamauchi T et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-769.
31. Arita Y et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
32. Yudkin JS et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction Arterioscler Thromb Vasc Biol 1999; 19:972-978.
33. Ziccardi P et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105: 804-809.
34. Yang WS et al. Weight reduction increases plasma levels of an adipose-derived antiinflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815-3819.
35. Maeda N et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-2099.
36. Kappes A and Loffler G. Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-α on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res 2000; 32: 548-554.
37. Fasshauer M et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2003; 301: 1045-1050.
38. Okamoto Y et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106: 2767-2770.
39. Ouchi N et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476.
40. Maeda N et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8: 731-737.
41. Weyer C et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86:1930-1935.
42. Ryo M et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004; 68:975-981.
43. Hoffstedt J et al. Adipose tissue adiponectin production and adiponectin serum concentration in human obesity and insulin resistance. J Clin Endocrinol Metab 2004; 89:1391-1396.
44. Engeli S et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003; 52: 942-947.
45. Ouchi N et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003; 42: 231-234.
46. Hotta K et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
47. Choi KM et al. Serum adiponectin concentrations predict developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin Endocrinol 2004; 61: 75-80.
48. Snehalatha C et al. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian indians. Diabetes Care 2003; 26: 3226-3229.
49. Spranger J et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226-228.
50. Yamamoto Y et al. Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab 2004; 89: 87-90.
51. Berg AH et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947-953.
52. Nawrocki AR et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor γ agonists. J Biol Chem 2006; 281: 2654-2660.
53. Yamauchi T et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-1295.
54. Wu X et al. Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 2003; 52:1355-1363.
55. Satoh H et al. Adenovirus-mediated adiponectin expression augments skeletal muscle insulin sensitivity in male Wistar rats. Diabetes 2005; 54: 1304-1313.
56. Fernandez-Real JM et al. Adiponectin is associated with vascular function independent of insulin sensitivity. Diabetes Care 2004; 27: 739-745.
57. Iwashima Y et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004; 43: 1318-1323.
58. Sung SH et al. Adiponectin, but not leptin or high-sensitivity C-reactive protein, is associated with blood pressure independently of general and abdominal adiposity. Hypertens Res 2008; 31: 633-640.
59. Devaraj S et al. Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop. Arterioscler Thromb Vasc Biol 2008; 28: 1368-1374.
60. Ohashi KN et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006; 47: 1108-1116.
61. Ouchi N et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 2004; 279: 1304-1309.
62. Kubota N et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277: 25863-25866.
63. Braun M et al. Cellular adhesion molecules on vascular smooth muscle cells. Cardiovasc Res 1999; 41: 395-401.
64. Pagano C et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 2005; 152: 113-118.
65. Zou CC et al. Serum adiponectin, resistin levels and non-alcoholic fatty liver disease in obese children. Endocr J 2005; 52: 519-524.
66. Aygun C et al. Serum levels of hepatoprotective peptide adiponectin in non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2006; 18: 175-180.
67. Ma H et al. Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2009; 24:233-237.
68. Hennige AM et al. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS ONE 2008; 3: e1765.
69. Haffner SM et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106:679-684.
70. Katsuki A et al. Troglitazone reduces plasma levels of tumour necrosis factor-α in obese patients with type 2 diabetes. Diabetes Obes Metab 2000; 2: 189-191.
71. Khanolkar MP et al. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus: an effect probably mediated by direct platelet PPARγ activation. Atherosclerosis 2008; 197:718-724.
72. Combs TP et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: potential mechanism of insulin sensitization. Endocrinology 2002; 143: 998-1007.
73. Yu JG et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51: 2968-2974.
74. Ikeda Y et al. Pioglitazone rapidly increases serum adiponectin levels in men with normal glucose tolerance. Diabetes Care 2007; 30: e48.
75. Libby P and Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator- activated receptor-α and peroxisome proliferator-activated receptor-γ agonists. Am J Cardiol 2007; 99: 27B-40B.
76. Guo KY et al. Effects of obesity on the relationship of leptin mRNA expression and adipocyte size in anatomically distinct fat depots in mice. Am J Physiol Regul Integr Comp Physiol 2004; 287: R112-R119.
77. Trayhurn P and Bing C. Appetite and energy balance signals from adipocytes. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1237-1249.
78. Hukshorn CJ et al. Leptin and the proinflammatory state associated with human obesity. J Clin Endocrinol Metab 2004; 89: 1773-1778.
79. Clement K and Langin D. Regulation of inflammation-related genes in human adipose tissue. J Intern Med 2007; 262: 422-430.
80. van Dielen FM et al. Leptin and soluble leptin receptor levels in obese and weight-losing individuals. J Clin Endocrinol Metab 2002; 87: 1708-1716.
81. Lahlou N et al. Soluble leptin receptor in serum of subjects with complete resistance to leptin: relation to fat mass. Diabetes 2000; 49: 1347-1352.
82. Ahima RS. Central actions of adipocyte hormones. Trends Endocrinol Metab 2005; 16:307-313.
83. Lafontan M. Fat cells: afferent and efferent messages define new approaches to treat obesity. Annu Rev Pharmacol Toxicol 2005; 45: 119-146.
84. Harris RB et al. Metabolic responses to leptin in obese db/db mice are strain-dependent. Am J Physiol Regul Integr Comp Physiol 2001; 281: R115-R132.
85. Remesar X et al. Is leptin an insulin counter-regulatory hormone? FEBS Lett 1997; 402:9-11.
86. Otero M et al. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett 2005; 579: 295-301.
87. Dunn SL et al. Feedback inhibition of leptin receptor/Jak2 signaling via Tyr1138 of the leptin receptor and suppressor of cytokine signaling 3. Mol Endocrinol 2005; 19:925-938.
88. Zhang F et al. Leptin: structure, function and biology. Vitam Horm 2005; 71: 345-372.
89. Emilsson V et al. Leptin treatment increases suppressors of cytokine signaling in central and peripheral tissues. FEBS Lett 1999; 455: 170-174.
90. Waki H and Tontonoz P. Endocrine functions of adipose tissue. Annu Rev Pathol 2007; 2: 31-56.
91. Slieker LJ et al. Regulation of expression of ob mRNA and protein by glucocorticoids and cAMP. J Biol Chem 1996; 271: 5301-5304.
92. Zhang Y et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
93. Inoue W et al. Leptin induces cyclooxygenase-2 via an interaction with interleukin-1β in the rat brain. Eur J Neurosci 2006; 24: 2233-2245.
94. Grunfeld C et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 1996; 97: 2152-2157.
95. Johnson PM et al. COX-2 inhibition attenuates anorexia during systemic inflammation without impairing cytokine production. Am J Physiol Endocrinol Metab 2002; 282:E650-E656.
96. Faggioni R et al. IL-1β mediates leptin induction during inflammation. Am J Physiol 1998; 274: R204-R208.
97. Sarraf P et al. Multiple cytokines and acute inflammation raise mouse leptin levels:potential role in inflammatory anorexia. J Exp Med 1997; 185: 171-175.
98. Fain JN et al. Stimulation of leptin release by arachidonic acid and prostaglandin E(2) in adipose tissue from obese humans. Metabolism 2001; 50: 921-928.
99. Sugiura K et al. Contribution of adipocytokines to low-grade inflammatory state as expressed by circulating C-reactive protein in Japanese men: comparison of leptin and adiponectin. Int J Cardiol 2008; 130: 159-164.
100. Singh P et al. Leptin induces C-reactive protein expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2007; 27: e302-e307.
101. Kang SM et al. Expression of leptin receptor (Ob-R) in human atherosclerotic lesions:potential role in intimal neovascularization. Yonsei Med J 2000; 41: 68-75.
102. Hajer GR, van Haeften TW, and Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008.
103. Hennige AM et al. Leptin downregulates insulin action through phosphorylation of serine-318 in insulin receptor substrate 1. FASEB J 2006; 20: 1206-1208.
104. Wang MY et al. OB-Rb gene transfer to leptin-resistant islets reverses diabetogenic phenotype. Proc Natl Acad Sci USA 1998; 95: 714-718.
105. Greenberg AS and McDaniel ML. Identifying the links between obesity, insulin resistance and β-cell function. Eur J Clin Invest 2002; 32: 24-34.
106. Ktori C, Shepherd PR, and O’Rourke L. TNF-α and leptin activate the α isoform of class II phosphoinositide 3-kinase. Biochem Biophys Res Commun 2003; 306: 139-143.
107. Cerman AA et al. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol 2008; 159: 820-626.
108. Wang Y et al. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol 2008; 158: 1134-1135.
109. Johnston A et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 2008; 159: 342-350.
110. Martin SS, Qasim A, and Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 2008; 52: 1201-1210.
111. Yu X et al. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc Natl Acad Sci USA 2008; 105: 14070-14075.
112. Oral EA et al. Leptin replacement therapy for lipodystrophy. New Engl J Med 2002; 346: 570-578.
113. Moller DE and Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005; 56: 45-62.
114. Steppan CM and Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 2002; 13: 18-23.
115. Holcomb IN et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 2000; 19: 4046-4055.
116. Kim KH et al. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 2001; 276: 11252-11256.
117. Steppan CM et al. The hormone resistin links obesity to diabetes. Nature 2001; 409:307-312.
118. Patel SD et al. Disulfide-dependent multimeric assembly of resistin family hormones. Science 2004; 304: 1154-1158.
119. Kusminski CM, McTernan PG, and Kumar S. Role of resistin in obesity, insulin resistance and Type II diabetes. Clin Sci 2005; 109: 243-256.
120. Banerjee RR and Lazar MA. Resistin: molecular history and prognosis. J Mol Med 2003; 81: 218-226.
121. Hartman HB et al. Mechanisms regulating adipocyte expression of resistin. J Biol Chem 2002; 277: 19754-19761.
122. Patel L et al. Resistin is expressed in human macrophages and directly regulated by PPARγ activators. Biochem Biophys Res Commun 2003; 300: 472-476.
123. Nogueiras R et al. Resistin is expressed in different rat tissues and is regulated in a tissue- and gender-specific manner. FEBS Lett 2003; 548: 21-27.
124. Nogueiras R et al. Regulation of resistin by gonadal, thyroid hormone, and nutritional status. Obes Res 2003; 11: 408-414.
125. Gui Y, Silha JV, and Murphy LJ. Sexual dimorphism and regulation of resistin, adiponectin, and leptin expression in the mouse. Obes Res 2004; 12: 1481-1491.
126. Lee JH et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration. J Clin Endocrinol Metab 2003; 88: 4848-4856.
127. Silha JV et al. Plasma resistin, adiponectin and leptin levels in lean and obese subjects:correlations with insulin resistance. Eur J Endocrinol 2003; 149: 331-335.
128. Yannakoulia M et al. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 2003; 88: 1730-1736.
129. Azuma K et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003; 11: 997-1001.
130. Degawa-Yamauchi M et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003; 88: 5452-5455.
131. Lee JH et al. Circulating resistin in lean, obese, and insulin-resistant mouse models: lack of association with insulinemia and glycemia. Am J Physiol Endocrinol Metab 2005; 288: E625-E632.
132. Mahadik SR, Deo SS, and Mehtalia SD. Association of adiposity, inflammation and atherosclerosis: role of adipocytokines and CRP in Asian Indian subjects. Metab Syndr Relat Disord 2008; 6: 121-128.
133. Piestrzeniewicz K et al. Resistin increases with obesity and atherosclerotic risk factors in patients with myocardial infarction. Metabolism 2008; 57: 488-493.
134. Rajala MW et al. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 2004; 53: 1671-1679.
135. Schaffler A et al. Identification of variables influencing resistin serum levels in patients with type 1 and type 2 diabetes mellitus. Horm Metab Res 2004; 36: 702-707.
136. Vendrell J et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines:relationships in obesity. Obes Res 2004; 12: 962-971.
137. Chen CC et al. Serum resistin level among healthy subjects: relationship to anthropometric and metabolic parameters. Metabolism 2005; 54: 471-475.
138. Farvid MS et al. Association of adiponectin and resistin with adipose tissue compartments, insulin resistance and dyslipidaemia. Diabetes Obes Metab 2005; 7: 406-413.
139. Maebuchi M et al. Low resistin levels in adipose tissues and serum in high-fat fed mice and genetically obese mice: development of an ELISA system for quantification of resistin. Arch Biochem Biophys 2003; 416: 164-170.
140. Savage DB et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator- activated receptor-γ action in humans. Diabetes 2001; 50: 2199-2202.
141. Hirosumi J et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-336.
142. Fujinami A et al. Enzyme-linked immunosorbent assay for circulating human resistin:resistin concentrations in normal subjects and patients with type 2 diabetes. Clin Chim Acta 2004; 339: 57-63.
143. Smith SR et al. A promoter genotype and oxidative stress potentially link resistin to human insulin resistance. Diabetes 2003; 52: 1611-1618.
144. Hegele RA et al. Elevated serum C-reactive protein and free fatty acids among nondiabetic carriers of missense mutations in the gene encoding lamin A/C (LMNA) with partial lipodystrophy. Arterioscler Thromb Vasc Biol 2003; 23: 111-116.
145. Juan CC et al. Suppressed gene expression of adipocyte resistin in an insulin-resistant rat model probably by elevated free fatty acids. Biochem Biophys Res Commun 2001; 289: 1328-1383.
146. Levy JR et al. Lipid metabolism and resistin gene expression in insulin-resistant Fischer 344 rats. Am J Physiol Endocrinol Metab 2002; 282: E626-E633.
147. Pfutzner A et al. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab 2003; 49: 571-576.
148. Stejskal D et al. Resistin concentrations in persons with type 2 diabetes mellitus and in individuals with acute inflammatory disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2003; 147: 63-69.
149. Youn BS et al. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004; 89: 150-156.
150. Bokarewa M et al. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174: 5789-5795.
151. Fu Y et al. Pro-inflammatory cytokine production and insulin sensitivity regulated by overexpression of resistin in 3T3-L1 adipocytes. Nutr Metab 2006; 3: 28.
152. Kaser S et al. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003; 309: 286-290.
153. Lu SC et al. Lipopolysaccharide increases resistin gene expression in vivo and in vitro. FEBS Lett 2002; 530: 158-162.
154. Rajala MW et al. Cell type-specific expression and coregulation of murine resistin and resistin-like molecule-α in adipose tissue. Mol Endocrinol 2002; 16: 1920-1930.
155. Fasshauer M et al. Tumor necrosis factor α is a negative regulator of resistin gene expression and secretion in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2001; 288: 1027-1031.
156. Shojima N et al. Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells. Diabetes 2002; 51: 1737-1744.
157. Al-Daghri N et al. Serum resistin is associated with C-reactive protein and LDL cholesterol in type 2 diabetes and coronary artery disease in a Saudi population. Cardiovasc Diabetol 2005; 4: 10.
158. Axelsson J et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 2006; 69: 596-604.
159. Bo S et al. Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes 2005; 29: 1315-1320.
160. Kawanami D et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004; 314: 415-419.
161. Verma S et al. Resistin promotes endothelial cell activation: further evidence of adipokine- endothelial interaction. Circulation 2003; 108: 736-740.
162. Burnett MS et al. The potential role of resistin in atherogenesis. Atherosclerosis 2005; 182: 241-248.
163. Calabro P et al. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 2004; 110: 3335-3340.
164. Jung HS et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 2006; 69: 76-85.
165. Reilly MP et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111: 932-939.
166. Senolt L et al. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 2007; 66: 458-463.
167. Schaffler A et al. Adipocytokines in synovial fluid. JAMA 2003; 290: 1709-1710.
168. Migita K et al. The serum levels of resistin in rheumatoid arthritis patients. Clin Exp Rheumatol 2006; 24: 698-701.